1. Home
  2. EFSC vs TRAX Comparison

EFSC vs TRAX Comparison

Compare EFSC & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enterprise Financial Services Corporation

EFSC

Enterprise Financial Services Corporation

N/A

Current Price

$62.55

Market Cap

2.1B

Sector

Finance

ML Signal

N/A

TRAX

First Tracks Biotherapeutics Inc. Ordinary Shares

N/A

Current Price

$50.31

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EFSC
TRAX
Founded
1988
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
1996
2026

Fundamental Metrics

Financial Performance
Metric
EFSC
TRAX
Price
$62.55
$50.31
Analyst Decision
Buy
Strong Buy
Analyst Count
7
12
Target Price
$69.57
★ $75.17
AVG Volume (30 Days)
210.3K
★ 776.1K
Earning Date
10-21-2026
11-03-2026
Dividend Yield
★ 2.31%
N/A
EPS Growth
★ 9.94
N/A
EPS
★ 3.54
N/A
Revenue
N/A
N/A
Revenue This Year
$3.10
N/A
Revenue Next Year
$6.95
N/A
P/E Ratio
$17.65
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.40
$15.69
52 Week High
$68.73
$54.78

Technical Indicators

Market Signals
Indicator
EFSC
TRAX
Relative Strength Index (RSI) 55.44 63.56
Support Level $61.82 $35.11
Resistance Level $68.08 N/A
Average True Range (ATR) 1.24 3.30
MACD 0.08 0.57
Stochastic Oscillator 35.47 61.08

Price Performance

Historical Comparison
EFSC
TRAX

About EFSC Enterprise Financial Services Corporation

Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Its Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.

About TRAX First Tracks Biotherapeutics Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Share on Social Networks: